967 results on '"Kerbel, Robert S."'
Search Results
2. Consensus guidelines for the use and interpretation of angiogenesis assays
3. ErbB2/Her2-dependent downregulation of a cell death-promoting protein BLNK in breast cancer cells is required for 3D breast tumor growth
4. On coalescent angiogenesis and the remarkable flexibility of blood vessels
5. Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1
6. Variable impact of three different antiangiogenic drugs alone or in combination with chemotherapy on multiple bone marrow-derived cell populations involved in angiogenesis and immunity
7. Vessel co-option in cancer
8. Development of Orthotopic and Spontaneous Metastatic Human Tumor Xenograft Models for Experimental Therapeutics
9. Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer
10. Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease
11. Preclinical impact of high dose intermittent antiangiogenic tyrosine kinase inhibitor pazopanib in intrinsically resistant tumor models
12. Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer?
13. The potential clinical promise of ‘multimodality’ metronomic chemotherapy revealed by preclinical studies of metastatic disease
14. Abstract 3998: Metronomic gemcitabine plus neratinib effectively inhibits the growth of human Her-2 positive breast cancer cells intracranially implanted into immunodeficient mice
15. Supplementary Figure Legends 1-2 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis
16. Data from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis
17. Supplementary Table 3 from Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors
18. Supplementary Figure 1 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis
19. Supplementary Video 3 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis
20. Data from Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors
21. Supplementary Tables S1-S4 from Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors
22. Supplementary materials and methods and legends for Supplementary Figures and Tables from Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors
23. Supplementary Video 4 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis
24. Supplementary Methods and Materials; Supplementary Figures S1-S4 from Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors
25. Supplementary Figures from Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors
26. Data from Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors
27. Supplementary Video 2 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis
28. Supplementary Table 1 from Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors
29. Supplementary Table 2 from Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors
30. Supplementary Figure 2 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis
31. Supplementary Video 1 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis
32. Supplementary Figure S2 from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
33. Supplementary Figure Legends from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
34. Supplementary Table S3 from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
35. Supplemental Figures S1-S6 from Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy
36. Data from Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers
37. Supplemental figures 1-3 from Potential Proinvasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy
38. Data from Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle–Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer
39. CCR Translation for the Article from Comparative Impact of Trastuzumab and Cyclophosphamide on HER-2–Positive Human Breast Cancer Xenografts
40. Supplemental Figures 1-5 and Methods from Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer
41. Supplemental Figures S1-S6 from Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle–Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer
42. Supplementary Materials and Methods from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
43. Supplemental Figures and Tables from Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers
44. Supplemental Methods from Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle–Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer
45. Supplemental Materials and Methods from Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers
46. Supplementary Methods and Materials, Figure 1 from Vascular Endothelial Growth Factor–Mediated Decrease in Plasma Soluble Vascular Endothelial Growth Factor Receptor-2 Levels as a Surrogate Biomarker for Tumor Growth
47. Data from Roles for Endothelin Receptor B and BCL2A1 in Spontaneous CNS Metastasis of Melanoma
48. Supplementary Methods from Combined Blockade of Integrin-α4β1 Plus Cytokines SDF-1α or IL-1β Potently Inhibits Tumor Inflammation and Growth
49. Supplementary Figure S1 from Low-dose Metronomic Combined with Intermittent Bolus-dose Cyclophosphamide Is an Effective Long-term Chemotherapy Treatment Strategy
50. Supplementary Figure Legend from Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.